Saxenda under the HSE Managed Access Protocol As of 2026, Saxenda (liraglutide) is the only weight-loss medication reimbursed under the Drugs Payment Scheme (DPS) or Medical Card (GMS) scheme in Ireland
YS edited and approved the final version of the manuscript
Our experienced aesthetic specialists specialize in delivering personalized care for every patient
Importantly, most GLP-1 receptor agonists carry a boxed warning about the risk of thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
And if we're going to have more people as renters for longer, that's going to expand the services economy at the expense of the goods economy
These are well established and each trial that you read where a GLP-1 is studied, alone or in combination with another incretin, you will find the first 4 adverse effects as the most common
